Section 174 R&D Capitalization: The 2022 Rule Change That Bankrupted Software Companies

Few provisions of the Tax Cuts and Jobs Act of 2017 caused as much downstream damage as the Section 174 amendment. The original TCJA bill was largely revenue-positive in the first decade and revenue-negative in years 11-20, requiring offsetting provisions to balance the budget on paper. One such offset was a delayed change to Section 174 that took effect in tax years beginning after December 31, 2021.

What the Rule Now Says

For tax years starting in 2022 and later, taxpayers must capitalize and amortize specified research and experimental (SRE) expenditures, rather than deducting them currently. The amortization periods:

• 5 years for domestic SRE expenditures, beginning at the midpoint of the year incurred.

• 15 years for foreign SRE expenditures, beginning at the midpoint of the year incurred.

The midyear convention means even domestic R&D incurred in January effectively gets only 10% deducted in year 1 (one half-year of a five-year amortization). The other 90% is recovered over years 2 through 6.

What Counts as SRE

The rule applies broadly to expenditures incurred in connection with the taxpayer's trade or business that represent research and development costs in the experimental or laboratory sense. The IRS expanded the scope to explicitly include:

• Software development costs — all of them, regardless of whether they would have been deductible under prior guidance.

• Wages, salaries, and benefits of personnel performing R&D activities.

• Cost of supplies and materials used in research.

• Contract research expenses (with limitations).

• Patent costs incurred in connection with R&D.

The inclusion of all software development was the bombshell. SaaS companies, app developers, fintech startups, AI labs, and gaming studios saw their primary expense category transformed from a current deduction into a five-year amortization.

The Cash Flow Disaster

For a software startup spending $5M annually on engineering payroll, the impact is staggering. Under prior law, the full $5M was deducted in the year incurred. Under amended Section 174, only $500,000 is deductible in year 1 (10% via mid-year convention). The remaining $4.5M is amortized over the following five years.

For a company with $5M in revenue and $5M in engineering costs, prior law would show $0 taxable income. Under amended Section 174, the company shows $4.5M of phantom taxable income — and owes federal and state tax on income that doesn't exist economically. Many cash-burning startups faced six- and seven-figure tax bills with no operating income to support them.

The R&D Tax Credit Interaction

The R&D tax credit under Section 41 remains available, and for many companies, it partially offsets the cash flow damage from Section 174. However, the credit is reduced for amounts capitalized — there is a basis adjustment requirement that prevents double-counting. The interaction is technical and requires careful coordination.

Foreign R&D Penalty

The 15-year amortization for foreign SRE expenditures is punitive — designed to discourage offshoring of R&D. Companies with development teams in India, Eastern Europe, Latin America, or Asia face a 15-year cost recovery for those wages. For a company spending $1M annually on offshore engineering, only about $33,000 is deductible in year 1.

Legislative Relief — The Tax Relief for American Families and Workers Act

After two years of bipartisan complaints from the technology sector, Congress has been working on Section 174 relief. The Tax Relief for American Families and Workers Act of 2024 — and several subsequent legislative efforts — proposed restoring full domestic R&D expensing for tax years 2022-2025, with a return to capitalization beginning in 2026 unless further extended.

The relief, when enacted, allows retroactive election to deduct previously capitalized domestic R&D, generating refund opportunities for companies that paid tax on phantom income in 2022-2024. Foreign R&D capitalization (15-year) is generally not addressed by the relief efforts.

What Companies Should Do Now

1. Document SRE expenditures rigorously by category, vendor, and geography. The split between domestic and foreign matters enormously.

2. Coordinate with the R&D tax credit study to optimize the interaction.

3. Model multi-year cash tax projections assuming both the current rule and any pending relief.

4. Consider Section 280C(c)(2) reduced credit election to avoid the basis reduction adjustment.

5. If relief is enacted, file amended returns or accounting method changes to recapture refunds.

Audit Implications for SEC Registrants

For audited companies, Section 174 capitalization creates significant deferred tax balances on the balance sheet. Auditors are scrutinizing:

• Identification of SRE costs and proper allocation.

• Domestic versus foreign classification.

• Coordination with R&D credit calculations.

• ASC 740 deferred tax assets and valuation allowance considerations.

• Proper disclosure in MD&A and the financial statement footnotes.

The Bottom Line

Section 174 is the most painful technical accounting provision affecting venture-backed, technology, and SaaS companies in this decade. Until comprehensive relief is enacted and signed into law, every R&D-heavy business should be modeling the cash impact and preparing accounting method change paperwork in case Congress acts.